We’re researching the history of oncology: What’s in it for you?

27 October 2017 1

The history of medicine has often been reduced to hagiography – a celebration of past events lacking critical scrutiny. The contemporary history of oncology, with its ‘breakthroughs’ and ‘disruptive’ innovations, has likewise been exposed to [more]

The history of medicine has often been reduced to hagiography – a celebration of past events lacking critical scrutiny. The contemporary history of oncology, with its ‘breakthroughs’ and ‘disruptive’ innovations, has likewise been... [ more ]

Ending the isolation: a guide to developing national rare cancers networks

27 October 2017 0

European Reference Networks can only work if member states designate and develop their own accredited specialist centres that can network across borders. Simon Crompton talks to some of the policy makers, clinicians and patient advocates [more]

European Reference Networks can only work if member states designate and develop their own accredited specialist centres that can network across borders. Simon Crompton talks to some of the policy makers, clinicians and patient ad... [ more ]

Building the clinical evidence on metformin and cancer

27 October 2017 2

Population studies, mouse models, and mechanistic studies all show that metformin, a cheap well-tolerated diabetes drug, impacts in some way on how some cancers develop and progress. Anna Wagstaff talks to clinicians and researchers building [more]

Population studies, mouse models, and mechanistic studies all show that metformin, a cheap well-tolerated diabetes drug, impacts in some way on how some cancers develop and progress. Anna Wagstaff talks to clinicians and researche... [ more ]

Omar Youssef: aesthetic surgery is not just a Western luxury

27 October 2017 0

Training Egypt’s breast surgeons in techniques of plastic surgery is giving survivors a better quality of life and transforming women’s attitudes towards the disease. Having proved it is possible in his own country, Omar Youssef [more]

Training Egypt’s breast surgeons in techniques of plastic surgery is giving survivors a better quality of life and transforming women’s attitudes towards the disease. Having proved it is possible in his own country, Omar Youssef i... [ more ]

How much is too much? Will someone please take charge of finding answers?

27 October 2017 2

Precision medicine was meant to see the end of ‘maximum tolerated dose’ as the standard for introducing new drugs. It hasn’t happened, and many patients continue to suffer unnecessary toxicity from overtreatment, with health services [more]

Precision medicine was meant to see the end of ‘maximum tolerated dose’ as the standard for introducing new drugs. It hasn’t happened, and many patients continue to suffer unnecessary toxicity from overtreatment, with health servi... [ more ]

Let’s be honest: our research efforts centre on drugs not patients

27 October 2017 5

Precision oncology is about understanding what is driving an individual’s cancer growth, resistance and metastasis, and then targeting those pathways accordingly. Our current research models are good at developing drugs to hit targets. They are [more]

Precision oncology is about understanding what is driving an individual’s cancer growth, resistance and metastasis, and then targeting those pathways accordingly. Our current research models are good at developing drugs to hit tar... [ more ]

Advanced breast cancer advocacy goes global

27 October 2017 0

The advanced breast cancer community has spent many years defining the treatment, care and support patients need to help them live longer and feel and function better. They’ve now formed an alliance to advocate for [more]

The advanced breast cancer community has spent many years defining the treatment, care and support patients need to help them live longer and feel and function better. They’ve now formed an alliance to advocate for those needs to ... [ more ]

Immunotherapy in relapsed refractory Hodgkin lymphoma

27 October 2017 0

A chromosomal alteration present in almost all patients with Hodgkin lymphoma makes the disease uniquely vulnerable to PD-1/PD-L1 immune checkpoint blockers. Astrid Pavlovsky reviews the trial evidence and clinical experience, and looks to the future [more]

A chromosomal alteration present in almost all patients with Hodgkin lymphoma makes the disease uniquely vulnerable to PD-1/PD-L1 immune checkpoint blockers. Astrid Pavlovsky reviews the trial evidence and clinical experience, and... [ more ]

Radiotherapy and immunotherapy: a beneficial liaison?

27 October 2017 0

Ralph Weichselbaum and colleagues explore how enhancing innate and adaptive immunity by combining radiotherapy and immune therapy could tip the balance of the host immune response to promote cure. This is a summary, by Janet [more]

Ralph Weichselbaum and colleagues explore how enhancing innate and adaptive immunity by combining radiotherapy and immune therapy could tip the balance of the host immune response to promote cure.... [ more ]

The do-nothing dilemma

27 October 2017 0

To treat or not to treat? Different people respond in different ways to learning they have lesions that may or may not develop into threatening cancers. Charlotte Huff talks to ‘patients’, doctors and psychologists about [more]

To treat or not to treat? Different people respond in different ways to learning they have lesions that may or may not develop into threatening cancers. Charlotte Huff talks to ‘patients’, doctors and psychologists about reaching ... [ more ]

Chuck Bogosta, President, UPMC International

27 October 2017 0

UPMC is a 14-billion-dollar integrated global health enterprise, closely linked to the University of Pittsburgh. Twenty years ago it opened a transplant hospital in Sicily. Since then, its International arm has expanded to build hospitals [more]

UPMC is a 14-billion-dollar integrated global health enterprise, closely linked to the University of Pittsburgh. Twenty years ago it opened a transplant hospital in Sicily. Since then, its International arm has expanded to build h... [ more ]
UA-77507851-1